BL&H, Clinigen Group, Hospira, AstraZeneca sales and marketing update

Clinigen's Clinigen Healthcare division granted BL&H exclusive rights to commercialize Foscavir foscarnet in South Korea. The companies will collaborate on regulatory approval for the product to treat herpes, cytomegalovirus (CMV) infection and CMV in hematopoietic stem cell transplant (HSCT) patients. They expect a decision from the Korea Food and Drug Administration by year end. Foscavir is already approved in Japan for use in HSCT patients. Clinigen has exclusive, global rights to Foscavir from AstraZeneca under an April 2010 deal. Terms were not disclosed. ...